vTv Therapeutics Inc (NASDAQ:VTVT) Announces Its Second Quarter Financial Results

0
1075
Drugs Tablets Pain Medication Pills Headache

vTv Therapeutics Inc (NASDAQ:VTVT) is a clinical stage pharmaceutical business that focuses on the development of solutions for unmet medical needs. The company unveiled its second quarter financial results for June 30, 2018 today. Asides from that, it has also given updates regarding the upcoming events as well as its most recent achievements.

Current state of affairs

The current chief executive officer of vTv Therapeutics Steve Holcombe opined, “Since our announcement regarding the topline results from Part B of the STEADFAST Study, we have continued to analyze the results from Parts A and B and are encouraged by our findings.”

Holcombe outlined that the rest of their programs were at the moment in their clinical development. The goal is to handle the type 1 diabetes in the most amicable way. The company struck collaboration with Huadong Medicine and the two are now pushing the GLP-1R program and the target is to face out type 2 diabetes.

The turn of events

Holcombe spoke in relation to diabetes, Alzheimer’s disease and the various inflammatory disorders terming them treatable. The official said that they were looking into long-term solutions that would save patients from the major discomfort.

Both the FDA and the scientific advisory board are major players that can help a huge deal in taking the development of the therapy to highest possible levels. The Azeliragon data analysis is still on course and the company seeks to realize the most impressive outcome in the near future.

The Simplic T-1 study is out to enroll a significant number of patients struggling with type 1 diabetes. The company reveals that the adaptive Phase 1/2 SimplicT-1 Study is at this point giving dosages to patients. It seeks to evaluate the effect of TTP399 as an add-on to insulin therapy and that study will go on for 12 weeks.

TTP399 has in recent studies showcased remarkable abilities in reducing HbA1c levels. The AGATA Study was one of them and its will help a huge deal in the fight against type 2 diabetes.

The company also seeks to advance its PDE4 program with Newsoara and this will take place in the course of the second quarter.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.